PL3515894T3 - Związki indazolu do zastosowania w urazach ścięgien i/lub więzadeł - Google Patents

Związki indazolu do zastosowania w urazach ścięgien i/lub więzadeł

Info

Publication number
PL3515894T3
PL3515894T3 PL17784404T PL17784404T PL3515894T3 PL 3515894 T3 PL3515894 T3 PL 3515894T3 PL 17784404 T PL17784404 T PL 17784404T PL 17784404 T PL17784404 T PL 17784404T PL 3515894 T3 PL3515894 T3 PL 3515894T3
Authority
PL
Poland
Prior art keywords
tendon
indazole compounds
ligament injuries
ligament
injuries
Prior art date
Application number
PL17784404T
Other languages
English (en)
Inventor
Badry Bursulaya
Andreas Fisch
James Paul LAJINESS
Rainer Machauer
Swapnil MALEKAR
Hank Michael James Petrassi
Farshad RAMAZANI
Anne-Catherine REMOND
Thomas Ullrich
Peggy USSELMANN
Eric Vangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3515894T3 publication Critical patent/PL3515894T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17784404T 2016-09-23 2017-09-21 Związki indazolu do zastosowania w urazach ścięgien i/lub więzadeł PL3515894T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398869P 2016-09-23 2016-09-23
EP17784404.0A EP3515894B1 (en) 2016-09-23 2017-09-21 Indazole compounds for use in tendon and/or ligament injuries
PCT/IB2017/055735 WO2018055550A1 (en) 2016-09-23 2017-09-21 Indazole compounds for use in tendon and/or ligament injuries

Publications (1)

Publication Number Publication Date
PL3515894T3 true PL3515894T3 (pl) 2021-10-25

Family

ID=60084023

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17784404T PL3515894T3 (pl) 2016-09-23 2017-09-21 Związki indazolu do zastosowania w urazach ścięgien i/lub więzadeł

Country Status (36)

Country Link
US (1) US10112907B2 (pl)
EP (1) EP3515894B1 (pl)
JP (1) JP7007374B2 (pl)
KR (1) KR102490953B1 (pl)
CN (1) CN109715608B (pl)
AR (1) AR109688A1 (pl)
AU (1) AU2017332867B2 (pl)
CL (1) CL2019000727A1 (pl)
CO (1) CO2019002616A2 (pl)
CR (1) CR20190145A (pl)
CU (1) CU24553B1 (pl)
CY (1) CY1124301T1 (pl)
DK (1) DK3515894T3 (pl)
DO (1) DOP2019000071A (pl)
EA (1) EA038510B1 (pl)
EC (1) ECSP19019589A (pl)
ES (1) ES2878585T3 (pl)
HR (1) HRP20211006T1 (pl)
HU (1) HUE054910T2 (pl)
IL (1) IL265066B (pl)
JO (1) JOP20190054B1 (pl)
LT (1) LT3515894T (pl)
MX (1) MX388377B (pl)
MY (1) MY196425A (pl)
PE (1) PE20190657A1 (pl)
PH (1) PH12019500327A1 (pl)
PL (1) PL3515894T3 (pl)
PT (1) PT3515894T (pl)
RS (1) RS62145B1 (pl)
RU (1) RU2749547C2 (pl)
SG (1) SG11201901146SA (pl)
SI (1) SI3515894T1 (pl)
TW (1) TWI651308B (pl)
UY (1) UY37412A (pl)
WO (1) WO2018055550A1 (pl)
ZA (1) ZA201900860B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EP3908279B1 (en) 2019-01-11 2024-08-28 Novartis AG Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
CA3235477A1 (en) * 2021-10-17 2023-04-20 Trigone Pharma Ltd. Compositions and methods for drug instillation into the urinary bladder
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343756A2 (en) * 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7105532B2 (en) 2000-12-19 2006-09-12 Smithkline Beecham Corporation Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
JP2013542960A (ja) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド 脂肪酸シンターゼ阻害剤
US9199979B2 (en) * 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
TWI629275B (zh) 2013-03-13 2018-07-11 賽諾菲公司 N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途

Also Published As

Publication number Publication date
ECSP19019589A (es) 2019-03-29
AU2017332867B2 (en) 2020-03-05
BR112019005578A2 (pt) 2019-06-11
CU24553B1 (es) 2021-11-04
AR109688A1 (es) 2019-01-16
JP7007374B2 (ja) 2022-01-24
IL265066B (en) 2021-06-30
CU20190028A7 (es) 2019-11-04
DK3515894T3 (da) 2021-07-05
EP3515894B1 (en) 2021-04-07
CO2019002616A2 (es) 2019-06-11
MX388377B (es) 2025-03-19
PT3515894T (pt) 2021-07-13
HUE054910T2 (hu) 2021-10-28
WO2018055550A1 (en) 2018-03-29
ES2878585T3 (es) 2021-11-19
CR20190145A (es) 2019-06-03
HRP20211006T1 (hr) 2021-09-17
SG11201901146SA (en) 2019-04-29
PH12019500327A1 (en) 2019-11-11
UY37412A (es) 2018-04-30
JOP20190054A1 (ar) 2019-03-21
CN109715608B (zh) 2022-08-05
LT3515894T (lt) 2021-07-26
JOP20190054B1 (ar) 2023-03-28
JP2019529453A (ja) 2019-10-17
KR102490953B1 (ko) 2023-01-19
TWI651308B (zh) 2019-02-21
PE20190657A1 (es) 2019-05-08
RU2019111883A (ru) 2020-10-23
CN109715608A (zh) 2019-05-03
KR20190053223A (ko) 2019-05-17
TW201815767A (zh) 2018-05-01
RU2019111883A3 (pl) 2020-11-05
US10112907B2 (en) 2018-10-30
CL2019000727A1 (es) 2019-05-17
EA038510B1 (ru) 2021-09-08
NZ751121A (en) 2025-03-28
ZA201900860B (en) 2021-06-30
DOP2019000071A (es) 2019-05-15
EA201990766A1 (ru) 2019-08-30
EP3515894A1 (en) 2019-07-31
RU2749547C2 (ru) 2021-06-15
RS62145B1 (sr) 2021-08-31
CA3033249A1 (en) 2018-03-29
CY1124301T1 (el) 2022-07-22
MY196425A (en) 2023-04-10
AU2017332867A1 (en) 2019-03-07
US20180086716A1 (en) 2018-03-29
SI3515894T1 (sl) 2021-08-31
MX2019003362A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
IL272596A (en) Pridopidine for use in the treatment of ALS
IL264763B (en) Aza-indazole compounds for use in tendon and/or ligament injuries
HUS2400004I1 (hu) Diaminopirimidin-P2X3 és P2X2/3 receptor modulátorok felhasználásra köhögés kezelésében
LT3075666T (lt) Įtaisas kosmose naudojamam aparatui laikyti ir išskleisti
IL251215A0 (en) Cannabinoid preparation and method for treating pain
IL249400A0 (en) Orthopedic splints and methods for their production
PL3362449T3 (pl) Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową
IL271020A (en) Tinostemustine for the treatment of sarcoma
SI3331610T1 (sl) Sredstva za uporabo pri zdravljenju gliomov
SI3268374T1 (sl) KV1.3 inhibitorji in njihova medicinska uporaba
GB201710793D0 (en) Apparatus and methods for thermally treating ligaments
PT3215157T (pt) Apilimod para utilização no tratamento de melanoma
IL256135A (en) Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
IL265066B (en) Indazole compounds for use in tendon and/or ligament injuries
IL274822A (en) Substances for the treatment of depression and migraine
SMT202200151T1 (it) Composizioni e metodi per l’uso nel trattamento di omocistinuria.
ZA201807136B (en) Compositions for use in treating tendon degeneration
PL3135337T3 (pl) Urządzenie do relaksu i odnowy ciała
IL251949A0 (en) Small organic molecules for use in the treatment of neuro-inflammatory diseases
PL3166660T3 (pl) Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona
EP3592332C0 (fr) Nouvelle solution visco-élastique et son utilisation en rhumatologie
GB201615844D0 (en) Agents for use in therapy
GB2541957B (en) Self-contained welfare unit for use in rail industry
PT3191112T (pt) Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
HK40007808A (en) Aza-indazole compounds for use in tendon and/or ligament injuries